Toll-like receptors targeting technology for the treatment of lymphoma

References

• Wolska A, Lech-Maranda E, Robak T. Toll-like receptors and their role in hematologic malignancies. Curr Mol Med. 2009;9:324–335.
   PubMed Web of Science ®Google Scholar
• Koff JL, Chihara D, Phan A, et al. To each its own: linking the Biology and Epidemiology of NHL subtypes. Curr Hematol Malig Rep. 2015;10:244–255. DOI:10.1007/s11899-015-0267-0
   PubMed Web of Science ®Google Scholar
• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019–5032. DOI:10.1182/blood-2011-01-293050
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts and figures. Vol. 2016. Atlanta: American Cancer Society; 2016.
   Google Scholar
• Ashworth A, Bernards R. Using functional genetics to understand breast cancer biology. Cold Spring Harb Perspect Biol. 2010;2:a003327. DOI:10.1101/cshperspect.a003327
   Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–2417. DOI:10.1056/NEJMoa062867
   PubMed Web of Science ®Google Scholar
• An X, Tiwari AK, Sun Y, et al. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010;34:1255–1268. DOI:10.1016/j.leukres.2010.04.016
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388:394–397. DOI:10.1038/41131
   PubMed Web of Science ®Google Scholar
• Hoffmann JA, Kafatos FC, Janeway CA, et al. Phylogenetic perspectives in innate immunity. Science. 1999;284:1313–1318.
   PubMed Web of Science ®Google Scholar
• Rock FL, Hardiman G, Timans JC, et al. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci U S A. 1998;95:588–593.
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Kawai T, Sanjo H, et al. TLR6: A novel member of an expanding toll-like receptor family. Gene. 1999;231:59–65.
   PubMed Web of Science ®Google Scholar
• Du X, Poltorak A, Wei Y, et al. Three novel mammalian toll-like receptors: gene structure, expression, and evolution. Eur Cytokine Netw. 2000;11:362–371.
   PubMed Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740–745. DOI:10.1038/35047123
   PubMed Web of Science ®Google Scholar
• Chuang T, Ulevitch RJ. Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells. Biochim Biophys Acta. 2001;1518:157–161.
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhang G, Hayden MS, et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science. 2004;303:1522–1526. DOI:10.1126/science.1094351
   PubMed Web of Science ®Google Scholar
• Muzio M, Bosisio D, Polentarutti N, et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol. 2000;164:5998–6004.
   PubMed Web of Science ®Google Scholar
• Visintin A, Mazzoni A, Spitzer JH, et al. Regulation of Toll-like receptors in human monocytes and dendritic cells. J Immunol. 2001;166:249–255
   PubMed Web of Science ®Google Scholar
• Sandor F, Buc M. Toll-like receptors. II. Distribution and pathways involved in TLR signalling. Folia Biol (Praha). 2005;51:188–197.
   PubMed Web of Science ®Google Scholar
• Bourke E, Bosisio D, Golay J, et al. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood. 2003;102:956–963. DOI:10.1182/blood-2002-11-3355
   PubMed Web of Science ®Google Scholar
• Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, et al. Toll-like receptors: lessons to learn from normal and malignant human B cells. Blood. 2008;112:2205–2213. DOI:10.1182/blood-2008-02-140673
   PubMed Web of Science ®Google Scholar
• Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol. 2002;168:4531–4537.
   PubMed Web of Science ®Google Scholar
• Visco C, Finotto S. Hepatitis C virus and diffuse large B-cell lymphoma: pathogenesis, behavior and treatment. World J Gastroenterol. 2014;20:11054–11061. DOI:10.3748/wjg.v20.i32.11054
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Govi S, Ponzoni M. The role of Helicobacter pylori eradication in the treatment of diffuse large B-cell and marginal zone lymphomas of the stomach. Curr Opin Oncol. 2013;25:470–479. DOI:10.1097/01.cco.0000432523.24358.15
   PubMed Web of Science ®Google Scholar
• Barr TA, Brown S, Ryan G, et al. TLR-mediated stimulation of APC: distinct cytokine responses of B cells and dendritic cells. Eur J Immunol. 2007;37:3040–3053. DOI:10.1002/eji.200636483
   PubMed Web of Science ®Google Scholar
• Bekeredjian-Ding I, Jego G. Toll-like receptors–sentries in the B-cell response. Immunology. 2009;128:311–323. DOI:10.1111/j.1365-2567.2009.03173.x
   PubMed Web of Science ®Google Scholar
• Isaza-Correa JM, Liang Z, van den Berg A, et al. Toll-like receptors in the pathogenesis of human B cell malignancies. J Hematol Oncol. 2014;7:57. DOI:10.1186/s13045-014-0057-5
   PubMed Web of Science ®Google Scholar
• Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335–376. DOI:10.1146/annurev.immunol.21.120601.141126
   PubMed Web of Science ®Google Scholar
• Lemaitre B, Nicolas E, Michaut L, et al. The dorsoventral regulatory gene cassette spatzle/toll/cactus controls the potent antifungal response in Drosophila adults. Cell. 1996;86:973–983.
   PubMed Web of Science ®Google Scholar
• Leadbetter EA, Rifkin IR, Hohlbaum AM, et al. Chromatin-igG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 2002;416:603–607. DOI:10.1038/416603a
   PubMed Web of Science ®Google Scholar
• Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303:1526–1529. DOI:10.1126/science.1093620
   PubMed Web of Science ®Google Scholar
• Tsan MF. Toll-like receptors, inflammation and cancer. Semin Cancer Biol. 2006;16:32–37. DOI:10.1016/j.semcancer.2005.07.004
   PubMed Web of Science ®Google Scholar
• Deng L, Wang C, Spencer E, et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell. 2000;103:351–361.
   PubMed Web of Science ®Google Scholar
• Wang C, Deng L, Hong M, et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature. 2001;412:346–351. DOI:10.1038/35085597
   PubMed Web of Science ®Google Scholar
• Wu H, Arron JR. TRAF6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology. Bioessays. 2003;25:1096–1105. DOI:10.1002/bies.10352
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11:373–384. DOI:10.1038/ni.1863
   PubMed Web of Science ®Google Scholar
• Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood. 2003;101:4500–4504. DOI:10.1182/blood-2002-11-3569
   PubMed Web of Science ®Google Scholar
• Ruprecht CR, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol. 2006;36:810–816. DOI:10.1002/eji.200535744
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A, Sallusto F. Toll-like receptors and innate immunity in B-cell activation and antibody responses. Curr Opin Immunol. 2007;19:268–274. DOI:10.1016/j.coi.2007.04.002
   PubMed Web of Science ®Google Scholar
• Isnardi I, Ng YS, Srdanovic I, et al. IRAK-4- and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity. 2008;29:746–757. DOI:10.1016/j.immuni.2008.09.015
   PubMed Web of Science ®Google Scholar
• Fillatreau S, Manz RA. Tolls for B cells. Eur J Immunol. 2006;36:798–801. DOI:10.1002/eji.200636040
   PubMed Web of Science ®Google Scholar
• Bekeredjian-Ding I, Inamura S, Giese T, et al. Staphylococcus aureus protein A triggers T cell-independent B cell proliferation by sensitizing B cells for TLR2 ligands. J Immunol. 2007;178:2803–2812.
   PubMed Web of Science ®Google Scholar
• Poeck H, Wagner M, Battiany J, et al. Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood. 2004;103:3058–3064. DOI:10.1182/blood-2003-08-2972
   PubMed Web of Science ®Google Scholar
• Gauld SB, Dal Porto JM, Cambier JC. B cell antigen receptor signaling: roles in cell development and disease. Science. 2002;296:1641–1642. DOI:10.1126/science.1071546
   PubMed Web of Science ®Google Scholar
• Muzio M, Bertilaccio MT, Simonetti G, et al. The role of toll-like receptors in chronic B-cell malignancies. Leuk Lymphoma. 2009;50:1573–1580. DOI:10.1080/10428190903115410
   PubMed Web of Science ®Google Scholar
• Kabelitz D. Expression and function of Toll-like receptors in T lymphocytes. Curr Opin Immunol. 2007;19:39–45. DOI:10.1016/j.coi.2006.11.007
   PubMed Web of Science ®Google Scholar
• Kelaidi C, Rollot F, Park S, et al. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia. 2004;18:1711–1716. DOI:10.1038/sj.leu.2403443
   PubMed Web of Science ®Google Scholar
• Arcaini L, Paulli M, Boveri E, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer. 2004;100:107–115. DOI:10.1002/cncr.11893
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Zucca E. Marginal-zone lymphoma. Crit Rev Oncol Hematol. 2007;63:245–256. DOI:10.1016/j.critrevonc.2007.04.009
   PubMed Web of Science ®Google Scholar
• Parsonnet J, Isaacson PG. Bacterial infection and MALT lymphoma. N Engl J Med. 2004;350:213–215. DOI:10.1056/NEJMp038200
   PubMed Web of Science ®Google Scholar
• Zucca E, Bertoni F, Roggero E, et al. Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. N Engl J Med. 1998;338:804–810. DOI:10.1056/NEJM199803193381205
   PubMed Web of Science ®Google Scholar
• Purdue MP, Lan Q, Wang SS, et al. A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma. Carcinogenesis. 2009;30:275–281. DOI:10.1093/carcin/bgn262
   PubMed Web of Science ®Google Scholar
• Nieters A, Beckmann L, Deeg E, et al. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun. 2006;7:615–624. DOI:10.1038/sj.gene.6364337
   PubMed Web of Science ®Google Scholar
• Forrest MS, Skibola CF, Lightfoot TJ, et al. Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma. Br J Haematol. 2006;134:180–183. DOI:10.1111/j.1365-2141.2006.06141.x
   PubMed Web of Science ®Google Scholar
• Hellmig S, Fischbach W, Goebeler-Kolve ME, et al. Association study of a functional Toll-like receptor 4 polymorphism with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. Leuk Lymphoma. 2005;46:869–872. DOI:10.1080/1042819050086451
   PubMed Web of Science ®Google Scholar
• Mantovani A, Garlanda C. Inflammation and multiple myeloma: the Toll connection. Leukemia. 2006;20:937–938. DOI:10.1038/sj.leu.2404229
   PubMed Web of Science ®Google Scholar
• Jego G, Bataille R, Geffroy-Luseau A, et al. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia. 2006;20:1130–1137. DOI:10.1038/sj.leu.2404226
   PubMed Web of Science ®Google Scholar
• Bohnhorst J, Rasmussen T, Moen SH, et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia. 2006;20:1138–1144. DOI:10.1038/sj.leu.2404225
   PubMed Web of Science ®Google Scholar
• Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470:115–119. DOI:10.1038/nature09671
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med. 2012;367:826–833. DOI:10.1056/NEJMoa1200710
   PubMed Web of Science ®Google Scholar
• Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475:101–105. DOI:10.1038/nature10113
   PubMed Web of Science ®Google Scholar
• Yan Q, Huang Y, Watkins AJ, et al. BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas. Haematologica. 2012;97:595–598. DOI:10.3324/haematol.2011.054080
   PubMed Web of Science ®Google Scholar
• Shaffer AL 3rd, Young RM, Staudt LM. Pathogenesis of human B cell lymphomas. Annu Rev Immunol. 2012;30:565–610. DOI:10.1146/annurev-immunol-020711-075027
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhao Y, Huang H, et al. Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-kappaB. Br J Haematol. 2010;150:543–553. DOI:10.1111/j.1365-2141.2010.08284.x
   PubMed Web of Science ®Google Scholar
• Muzio M, Scielzo C, Bertilaccio MT, et al. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol. 2009;144:507–516. DOI:10.1111/j.1365-2141.2008.07475.x
   PubMed Web of Science ®Google Scholar
• Suarez F, Lortholary O, Hermine O, et al. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006;107:3034–3044. DOI:10.1182/blood-2005-09-3679
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Ernberg I, Copie-Bergman C. Infectious agents and lymphoma development: molecular and clinical aspects. J Intern Med. 2009;265:421–438. DOI:10.1111/j.1365-2796.2009.02083.x
   PubMed Web of Science ®Google Scholar
• Kaplan LD. HIV-associated lymphoma. Best Pract Res Clin Haematol. 2012;25:101–117. DOI:10.1016/j.beha.2012.01.001
   PubMed Web of Science ®Google Scholar
• Roschewski M, Wilson WH. EBV-associated lymphomas in adults. Best Pract Res Clin Haematol. 2012;25:75–89. DOI:10.1016/j.beha.2012.01.005
   PubMed Web of Science ®Google Scholar
• Salam I, Durai D, Murphy JK, et al. Regression of primary high-grade gastric B-cell lymphoma following Helicobacter pylori eradication. Eur J Gastroenterol Hepatol. 2001;13:1375–1378.
   PubMed Web of Science ®Google Scholar
• Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993;342:575–577.
   PubMed Web of Science ®Google Scholar
• Adam P, Schmausser B, Gobeler-Kolve M, et al. Gastric extranodal marginal zone B-cell lymphomas of MALT type exclusively express Toll-like receptor 4 in contrast to other lymphomas infiltrating the stomach. Ann Oncol. 2008;19:566–569. DOI:10.1093/annonc/mdm485
   PubMed Web of Science ®Google Scholar
• Henault M, Lee LN, Evans GF, et al. The human Burkitt lymphoma cell line Namalwa represents a homogenous cell system characterized by high levels of Toll-like receptor 9 and activation by CpG oligonucleotides. J Immunol Methods. 2005;300:93–99. DOI:10.1016/j.jim.2005.02.012
   PubMed Web of Science ®Google Scholar
• Smith TJ, Yamamoto K, Kurata M, et al. Differential expression of Toll-like receptors in follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphoma. Exp Mol Pathol. 2010;89:284–290. DOI:10.1016/j.yexmp.2010.08.003
   PubMed Web of Science ®Google Scholar
• Lutzker S, Rothman P, Pollock R, et al. Mitogen- and IL-4-regulated expression of germ-line Ig gamma 2b transcripts: evidence for directed heavy chain class switching. Cell. 1988;53:177–184.
   PubMed Web of Science ®Google Scholar
• He B, Qiao X, Cerutti A. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol. 2004;173:4479–4491.
   PubMed Web of Science ®Google Scholar
• Xu W, Santini PA, Matthews AJ, et al. Viral double-stranded RNA triggers Ig class switching by activating upper respiratory mucosa B cells through an innate TLR3 pathway involving BAFF. J Immunol. 2008;181:276–287.
   PubMed Web of Science ®Google Scholar
• Aranburu A, Ceccarelli S, Giorda E, et al. TLR ligation triggers somatic hypermutation in transitional B cells inducing the generation of IgM memory B cells. J Immunol. 2010;185:7293–7301. DOI:10.4049/jimmunol.1002722
   PubMed Web of Science ®Google Scholar
• Capolunghi F, Cascioli S, Giorda E, et al. CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. J Immunol. 2008;180:800–808.
   PubMed Web of Science ®Google Scholar
• Jahrsdorfer B, Muhlenhoff L, Blackwell SE, et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res. 2005;11:1490–1499. DOI:10.1158/1078-0432.CCR-04-1890
   PubMed Web of Science ®Google Scholar
• Spaner DE, Shi Y, White D, et al. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia. 2006;20:286–295. DOI:10.1038/sj.leu.2404061
   PubMed Web of Science ®Google Scholar
• Wolska A, Cebula-Obrzut B, Smolewski P, et al. Effects of Toll-like receptor 7 and Toll-like receptor 9 signaling stimulators and inhibitors on chronic lymphocytic leukemia cells ex vivo and their interactions with cladribine. Leuk Lymphoma. 2013;54:1268–1278. DOI:10.3109/10428194.2012.741233
   PubMed Web of Science ®Google Scholar
• Decker T, Schneller F, Sparwasser T, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood. 2000;95:999–1006.
   PubMed Web of Science ®Google Scholar
• Reid GS, She K, Terrett L, et al. CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response. Blood. 2005;105:3641–3647. DOI:10.1182/blood-2004-06-2468
   PubMed Web of Science ®Google Scholar
• Wang L, Zhao Y, Qian J, et al. Toll-like receptor-4 signaling in mantle cell lymphoma: effects on tumor growth and immune evasion. Cancer. 2013;119:782–791. DOI:10.1002/cncr.27792
   PubMed Web of Science ®Google Scholar
• Corthals SL, Wynne K, She K, et al. Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia. Br J Haematol. 2006;132:452–458. DOI:10.1111/j.1365-2141.2005.05893.x.
   PubMed Web of Science ®Google Scholar
• Lampropoulou V, Hoehlig K, Roch T, et al. TLR-activated B cells suppress T cell-mediated autoimmunity. J Immunol. 2008;180:4763–4773.
   PubMed Web of Science ®Google Scholar
• Sayi A, Kohler E, Toller IM, et al. TLR-2-activated B cells suppress Helicobacter-induced preneoplastic gastric immunopathology by inducing T regulatory-1 cells. J Immunol. 2011;186:878–890. DOI:10.4049/jimmunol.1002269
   PubMed Web of Science ®Google Scholar
• Tzankov A, Meier C, Hirschmann P, et al. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma. Haematologica. 2008;93:193–200. DOI:10.3324/haematol.11702
   PubMed Web of Science ®Google Scholar
• Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer. 2009;9:57–63. DOI:10.1038/nrc2541
   PubMed Web of Science ®Google Scholar
• Cho YJ, Ahn BY, Lee NG, et al. A combination of E. coli DNA fragments and modified lipopolysaccharides as a cancer immunotherapy. Vaccine. 2006;24:5862–5871. DOI:10.1016/j.vaccine.2006.04.048
   PubMed Web of Science ®Google Scholar
• Dunne A, Marshall NA, Mills KH. TLR based therapeutics. Curr Opin Pharmacol. 2011;11:404–411. DOI:10.1016/j.coph.2011.03.004
   PubMed Web of Science ®Google Scholar
• Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 2008;27:161–167. DOI:10.1038/sj.onc.1210911
   PubMed Web of Science ®Google Scholar
• Weiner GJ. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J Leukoc Biol. 2000;68:455–463.
   PubMed Web of Science ®Google Scholar
• Ben Abdelwahed R, Cosette J, Donnou S, et al. Lymphoma B-cell responsiveness to CpG-DNA depends on the tumor microenvironment. J Exp Clin Cancer Res. 2013;32:18. DOI:10.1186/1756-9966-32-18
   PubMed Web of Science ®Google Scholar
• Wei MQ, Mengesha A, Good D, et al. Bacterial targeted tumour therapy-dawn of a new era. Cancer Lett. 2008;259:16–27. DOI:10.1016/j.canlet.2007.10.034
   PubMed Web of Science ®Google Scholar
• Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196–200. DOI:10.1038/ni758
   PubMed Web of Science ®Google Scholar
• Vollmer J, Weeratna R, Payette P, et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol. 2004;34:251–262. DOI:10.1002/eji.200324032
   PubMed Web of Science ®Google Scholar
• Dorn A, Kippenberger S. Clinical application of CpG-, non-CpG-, and antisense oligodeoxynucleotides as immunomodulators. Curr Opin Mol Ther. 2008;10:10–20.
   PubMed Web of Science ®Google Scholar
• Goodman MG, Wormsley SB, Spinosa JC, et al. Loxoribine induces chronic lymphocytic leukemia B cells to traverse the cell cycle. Blood. 1994;84:3457–3464.
   PubMed Web of Science ®Google Scholar
• Pellacani A, Tosi P, Zinzani PL, et al. Cytotoxic combination of loxoribine with fludarabine and mafosfamide on freshly isolated B-chronic lymphocytic leukemia cells. Leuk Lymphoma. 1999;33:147–153. DOI:10.3109/10428199909093736
   PubMed Web of Science ®Google Scholar
• Voo KS, Foglietta M, Percivalle E, et al. Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. Int J Cancer. 2014;135:2834–2846. DOI:10.1002/ijc.28937
   PubMed Web of Science ®Google Scholar
• Nicodeme E, Jeffrey KL, Schaefer U, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468:1119–1123. DOI:10.1038/nature09589
   PubMed Web of Science ®Google Scholar
• Chapuy B, McKeown MR, Lin CY, et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell. 2013;24:777–790. DOI:10.1016/j.ccr.2013.11.003
   PubMed Web of Science ®Google Scholar
• Melief CJ, van Hall T, Arens R, et al. Therapeutic cancer vaccines. J Clin Invest. 2015;125:3401–3412. DOI:10.1172/JCI80009
   PubMed Web of Science ®Google Scholar
• Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A. 1995;92:11810–11813.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909–915. DOI:10.1038/nm1100
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Lee S, Moschos SJ, et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine±granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res. 2009;15:1443–1451. DOI:10.1158/1078-0432.CCR-08-1231
   PubMed Web of Science ®Google Scholar
• Zom GG, Khan S, Filippov DV, et al. TLR ligand-peptide conjugate vaccines: toward clinical application. Adv Immunol. 2012;114:177–201. DOI:10.1016/B978-0-12-396548-6.00007-X
   PubMed Web of Science ®Google Scholar
• Wen Y, Collier JH. Supramolecular peptide vaccines: tuning adaptive immunity. Curr Opin Immunol. 2015;35:73–79. DOI:10.1016/j.coi.2015.06.007
   PubMed Web of Science ®Google Scholar
• Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol. 2000;164:944–953.
   PubMed Web of Science ®Google Scholar
• Deres K, Schild H, Wiesmuller KH, et al. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature. 1989;342:561–564. DOI:10.1038/342561a0
   PubMed Web of Science ®Google Scholar
• Zom GG, Khan S, Britten CM, et al. Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates. Cancer Immunol Res. 2014;2:756–764. DOI:10.1158/2326-6066.CIR-13-0223
   PubMed Web of Science ®Google Scholar
• Willems MM, Zom GG, Khan S, et al. N-tetradecylcarbamyl lipopeptides as novel agonists for Toll-like receptor 2. J Med Chem. 2014;57:6873–6878. DOI:10.1021/jm500722p
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Butterfield LH, Tarhini AA, et al. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012;62:309–335. DOI:10.3322/caac.20132
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10:787–796. DOI:10.1038/nri2868
   PubMed Web of Science ®Google Scholar
• Johansen P, Mohanan D, Martinez-Gomez JM, et al. Lympho-geographical concepts in vaccine delivery. J Control Release. 2010;148:56–62. DOI:10.1016/j.jconrel.2010.05.019
   PubMed Web of Science ®Google Scholar
• Lee IH, Kwon HK, An S, et al. Imageable antigen-presenting gold nanoparticle vaccines for effective cancer immunotherapy in vivo. Angew Chem Int Ed Engl. 2012;51:8800–8805. DOI:10.1002/anie.201203193
   PubMed Web of Science ®Google Scholar
• Jeanbart L, Ballester M, de Titta A, et al. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes. Cancer Immunol Res. 2014;2:436–447. DOI:10.1158/2326-6066.CIR-14-0019-T
   PubMed Web of Science ®Google Scholar
• Qian Y, Jin H, Qiao S, et al. Targeting dendritic cells in lymph node with an antigen peptide-based nanovaccine for cancer immunotherapy. Biomaterials. 2016;98:171–183. DOI:10.1016/j.biomaterials.2016.05.008
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12:265–277. DOI:10.1038/nrc3258
   PubMed Web of Science ®Google Scholar
• Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol. 2001;19:47–64. DOI:10.1146/annurev.immunol.19.1.47
   PubMed Web of Science ®Google Scholar
• Davis ID, Jefford M, Parente P, et al. Rational approaches to human cancer immunotherapy. J Leukoc Biol. 2003;73:3–29.
   PubMed Web of Science ®Google Scholar
• Drobits B, Holcmann M, Amberg N, et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest. 2012;122:575–585. DOI:10.1172/JCI61034
   PubMed Web of Science ®Google Scholar
• Stary G, Bangert C, Tauber M, et al. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med. 2007;204:1441–1451. DOI:10.1084/jem.20070021
   PubMed Web of Science ®Google Scholar
• Cubillos-Ruiz JR, Engle X, Scarlett UK, et al. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest. 2009;119:2231–2244. DOI:10.1172/JCI37716
   PubMed Web of Science ®Google Scholar
• Mukherji B, Chakraborty NG, Yamasaki S, et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci U S A. 1995;92:8078–8082.
   PubMed Web of Science ®Google Scholar
• Carvalho A, Cunha C, Almeida AJ, et al. The rs5743836 polymorphism in TLR9 confers a population-based increased risk of non-Hodgkin lymphoma. Genes Immun. 2012;13:197–201. DOI:10.1038/gene.2011.59
   PubMed Web of Science ®Google Scholar
• Link BK, Ballas ZK, Weisdorf D, et al. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother. 2006;29:558–568. DOI:10.1097/01.cji.0000211304.60126.8f
   PubMed Web of Science ®Google Scholar
• Jahrsdorfer B, Wooldridge JE, Blackwell SE, et al. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol. 2005;77:378–387. DOI:10.1189/jlb.0604373
   PubMed Web of Science ®Google Scholar
• Schimmer AD, Munk-Pedersen I, Minden MD, et al. Bcl-2 and apoptosis in chronic lymphocytic leukemia. Curr Treat Options Oncol. 2003;4:211–218.
   PubMedGoogle Scholar
• Decker T, Hipp S, Kreitman RJ, et al. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood. 2002;99:1320–1326.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105:49–53. DOI:10.1182/blood-2004-03-0796
   PubMed Web of Science ®Google Scholar
• Damiano V, Caputo R, Bianco R, et al. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. Clin Cancer Res. 2006;12:577–583. DOI:10.1158/1078-0432.CCR-05-1943
   PubMed Web of Science ®Google Scholar
• Anwar MA, Basith S, Choi S. Negative regulatory approaches to the attenuation of Toll-like receptor signaling. Exp Mol Med. 2013;45:e11. DOI:10.1038/emm.2013.28
   PubMed Web of Science ®Google Scholar
• Dalpke A, Heeg K, Bartz H, et al. Regulation of innate immunity by suppressor of cytokine signaling (SOCS) proteins. Immunobiology. 2008;213:225–235. DOI:10.1016/j.imbio.2007.10.008
   PubMed Web of Science ®Google Scholar
• Weniger MA, Melzner I, Menz CK, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene. 2006;25:2679–2684. DOI:10.1038/sj.onc.1209151
   PubMed Web of Science ®Google Scholar
• Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev. 2004;199:227–250. DOI:10.1111/j.0105-2896.2004.00144.x
   PubMed Web of Science ®Google Scholar
• Kelly PN, Romero DL, Yang Y, et al. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. J Exp Med. 2015;212:2189–2201. DOI:10.1084/jem.20151074
   PubMed Web of Science ®Google Scholar
• Ferrao R, Zhou H, Shan Y, et al. IRAK4 dimerization and trans-autophosphorylation are induced by Myddosome assembly. Mol Cell. 2014;55:891–903. DOI:10.1016/j.molcel.2014.08.006
   PubMed Web of Science ®Google Scholar
• Wang JQ, Jeelall YS, Beutler B, et al. Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance. J Exp Med. 2014;211:413–426. DOI:10.1084/jem.20131424
   PubMed Web of Science ®Google Scholar
• Kao DD, Oldebeken SR, Rai A, et al. Tumor necrosis factor-alpha-mediated suppression of dual-specificity phosphatase 4: crosstalk between NFkappaB and MAPK regulates endothelial cell survival. Mol Cell Biochem. 2013;382:153–162. DOI:10.1007/s11010-013-1730-7
   PubMed Web of Science ®Google Scholar